Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cellceutix Corp anti-psoriasis drug Prurisol meets primary endpoint of clinical trial


Thursday, 7 Aug 2014 09:03am EDT 

Cellceutix Corp:Says it has just received notice that the data from its phase 1 trial of its anti-psoriasis drug candidate Prurisol for the conversion of Prurisol to abacavir indicated the areas are within passing Bioequivalency limits.Says it believes it has met the primary endpoints and objectives of the study.Says it is developing Prurisol under guidance from the U.S. Food and Drug Administration that a 505(b)(2) designation is an acceptable pathway to expedite development of the compound for treating psoriasis.Upon receipt of the final report Cellceutix will schedule a meeting with the FDA to advance Prurisol into a Phase 2/3 clinical trial as quickly as possible. 

Company Quote

4.29
 --
24 Dec 2014